Updated:
CTT Pharmaceutical Holdings
CTT Pharmaceutical Holdings is a dormant public shell that once targeted specialty pharma acquisitions. No active investment mandate exists.
CTT Pharmaceutical Holdings
CTT Pharmaceutical Holdings incorporated as a for-profit entity focused on acquiring and developing treatments in the pain management and critical care markets. Public record shows the company pursued a reverse merger path in the mid-2010s, attempting to commercialize a fast-dissolving drug delivery technology. The venture never reached revenue stage, and subsequent disclosures dried up after 2017. Its intended strategy centered on late-stage pharmaceutical assets requiring commercialization partnerships rather than direct drug discovery. The firm's single named platform was a wafer-based transdermal delivery system, though no FDA approvals or manufacturing contracts materialized. Geographic exposure was limited to Canada, where the company maintained its initial incorporation, with attempted distribution tie-ins in the United States that went unconsummated. The management roster at its peak included Roger Duffield as CFO and directors drawn from early-stage health sciences. No institutional capital was ever reported raised; the entity funded operations through small-scale equity placements before its public listing lapsed. There are no adjacent vehicles, philanthropic arms, or co-investment clubs associated with CTT, and no team members remain actively employed per current corporate registries. The structural differentiator here is a cautionary one: CTT represents a fully dormant public shell — a once-ambitious drug-delivery platform that ran out of operating runway before institutionalization. For an allocator performing manager due diligence, its significance lies entirely in confirming that no active investment operations exist and that any market presence is historical.
General information
Firm type
Asset Manager
Year founded
—
AUM
Undisclosed
Location
Region
—
Country
—
City
—
Corporate office
—
Sector focus
Frequently asked questions
Does CTT Pharmaceutical Holdings still operate as an active investment firm?
No. All available public record indicates CTT Pharmaceutical Holdings is a dormant or defunct publicly incorporated shell. It last filed meaningful activity with Canadian securities regulators in the mid-2010s, and its corporate registration has since lapsed. No investment professionals, portfolio positions, or operational cash flows are currently associated with the entity.
What was CTT Pharmaceutical Holdings' original investment strategy?
The firm aimed to in-license and commercialize late-stage specialty pharmaceutical products, particularly in pain management and critical care. Its primary asset was a fast-dissolving oral wafer delivery technology. The strategy never transitioned from development to revenue generation, and no product ever received regulatory approval.
Who ran investment decisions at CTT?
The last named officer in public filings is Roger Duffield, who held the position of chief financial officer. No dedicated chief investment officer or investment committee structure was ever disclosed, consistent with the company's status as a pre-revenue operating entity rather than a fund manager or family office deploying third-party or proprietary capital.
Is there any relation between CTT and a family office structure?
None in any verifiable sense. While the name "Pharmaceutical Holdings" could suggest a holding company for family wealth, CTT was incorporated as a standard operating company pursuing public-market listing. There is no evidence of a single-family sourcing event, no wealth-origin disclosure, and no family principals associated with its governance.
What should an allocator conclude from CTT's current profile?
The entity carries no investable thesis, no management team, and no portfolio. For institutional allocators conducting fund-manager searches or co-investment diligence, CTT is irrelevant. Its one utility is in negative screening: confirming that a name surfacing in legacy databases does not represent an active investment opportunity or counterparty risk.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on asset managers?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: